Infinitus Clinical Research Consolidates - Sino-Indian CRO Enhances Core Capabilities

Thursday, March 18, 2010 Research News
Email Print This Page Comment bookmark
Font : A-A+

BANGALORE, India, March 17, 2010 Infinitus ClinicalResearch is continuing to pioneer its unique strategy. This is based on thefollowing elements:

"As former Vice-President for clinical drug development with a major USPharma company" said CEO, Roy Drucker, "I was frustrated by the unexploitedpotential of India and China. Large Western CROs were inevitably forced togive up part of the cost advantage of those countries because of operatingexpense back at base camp. The best local players scored better on price andsatisfied study deadline requirements but were incapable of assuming aproduct development partnership role. We strive to deliver the best of bothworlds at Infinitus. "

"Infinitus has also recognized the opacity of India and China to smallerWestern companies wishing to conduct product or corporate transactions inthese countries. With established strategic partners in both locations we arecurrently working with clients who have products for which they are seekingto achieve marketing presence in India and China, as well as executing M&Amandates on behalf of Western clients. More recently, we have begun to servethe needs of Chinese clients wishing to bring their products to the West."

Roy Drucker: "The world of clinical product development is changing veryrapidly and there are huge advantages available to those who are prepared toexplore unfamiliar territory. Infinitus can make that exploration a positiveexperience."

About Infinitus:

Infinitus executes its clinical research activities exclusively in Asia.

Benefitting from not having to bear the overheads of a large westerninfrastructure, the orientation is very much towards serving the needs of aninternational clientele which includes early stage life science companiesresearching pharmaceutical and biotechnology products as well as medicaldevices.

Operating out of Bangalore in India and Nanjing in China, it is led by amanagement team with extensive experience of conceiving and executing entireclinical product development programmes for global registration purposes, aswell as substantial hands-on operational experience in the relevant territory.

Its objective is to assist in curtailing the cost of product developmentin its clinical stages while at the same time expediting execution and addingvalue in every way possible."Our conviction is that excellent medical science underpins excellent clinical research and education. This is reflected in our ongoing collaborative relationship with the Department of Pharmacology at the University of Oxford, where we have a Coordinating Centre. We recognize that a significant part of our client base is in the USA and our North American office will open shortly. We are also progressing a major oncology initiative which will enable Infinitus to deliver unparalleled speed, quality and prices for studies in all phases."

SOURCE Infinitus Clinical Research Pvt. Ltd.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store